Xeris Biopharma (XERS) Q3 2026 Earnings Call Transcript

Xeris reported Q3 2026 revenue of $107.2 million, up 44% year over year, with adjusted EBITDA rising 77% to $30.8 million and net income increasing to $11.3 million from $0.6 million. Management raised 2026 revenue guidance to $395 million–$405 million and its 2030 outlook to more than $1 billion from $750 million, while saying Recorlev could reach $1 billion in annual net revenue three to four years earlier than previously projected. The company also retired $34 million of 8.00% convertible notes, and expects to initiate the XP-8121 Phase III Cornerstone study by year-end 2026, with top-line data expected in late 2028.

Analysis

The key underwriting question is whether commercial-team productivity converts into durable net patient additions—not simply more referrals. Recorlev’s prior-authorization burden makes growth operationally intensive: added volume may bring ongoing patient-support and access costs, while payer decisions and gross-to-net adjustments can make reported sales noisier than prescription trends. Updated screening guidance may widen the funnel, but it does not itself ensure diagnosis, treatment, or coverage; evidence generation and conversion rates are the real catalysts.

Near term (days to 1–3 months), the raised outlook and strong execution can support sentiment, but the market may extrapolate one quarter’s acceleration too aggressively. Track Q4 Recorlev starts and net revenue, and whether Gvoke prescriptions translate into net sales after the Medicaid adjustment. Management’s higher SG&A plan is a real reinvestment burden, not just a footnote to growth. Over 6–18 months, successful investment across three brands could improve operating leverage; failure to sustain growth would expose the cost base. XP-8121 is a long-dated option, not a near-term earnings driver: pivotal data are expected in late 2028, so its peak-sales ambition should not be capitalized as established value. Patent grants support the opportunity but do not remove validity, enforcement, or clinical risks.

Contrarian point: the attractive narrative is broadening demand, while the less visible risk is that access friction and commercial spend absorb more of each incremental dollar than headline growth implies. No valuation or share-price context is supplied, so the results alone do not establish that XERS is inexpensive.

Key Decisions for Investors

• Do not chase solely on the guidance increase. For an event-driven book, consider a staged, modest long in XERS only after checking valuation and liquidity; the upside case is continued Recorlev conversion and operating leverage, while the downside is growth deceleration against a larger SG&A base.
• Use Q4 and the next report as the key confirmation window: monitor Recorlev new-patient starts and net revenue, Gvoke prescriptions versus net sales, and gross margin. Reassess the long thesis if Recorlev momentum materially slows or Gvoke prescription growth again fails to translate into revenue.
• Treat the 2030 outlook and XP-8121 sales potential as unproven scenarios, not near-term catalysts. Verify study initiation, enrollment progress, and development spending; a delay to the Phase III program or a materially weaker clinical update would reduce the pipeline component of the thesis.
• Watch access and realization metrics: prior-authorization approval/conversion, persistence, and gross-to-net deductions. Deterioration there would falsify the assumption that broader screening reliably produces profitable treated patients.